DuoRich Sustained Release Tablets 10/1000 mg
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
MFDS item code 202106826 · Approved 2021.10.08
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes by the combined administration of dapagliflozin and metformin. It may be particularly helpful in patients who do not have adequate glycemic control and have cardiovascular disease or risk factors for cardiovascular disease. However, the impact on cardiovascular events should be guided by a healthcare professional.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same or a therapeutically appropriate dose close to the metformin dose the patient was taking. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from another glucose-lowering drug. Because changes may result in altered blood glucose control, any change in treatment in patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted through the kidneys, and renal function is more likely to decline in elderly patients; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used for the treatment of diabetes and should not be used in patients with impaired kidney function or serious infections and cardiac issues. It can rarely cause a severe metabolic disease called lactic acidosis. If you experience unusual symptoms or discomfort, consult a physician immediately. Caution is advised when taking this medication with insulin or other diabetes medications as hypoglycemia may occur, and appropriate actions should be taken if hypoglycemic symptoms appear. Elderly patients with impaired kidney function or fluid deficiency should regularly monitor their kidney function and fluid status before and during the use of this medication. This medication may increase the risk of genital infections or urinary tract infections, so prompt treatment should be sought if any infection symptoms arise. Additionally, this medication may slightly lower blood pressure, so patients at risk of hypotension should carefully monitor their blood pressure. Pregnant or breastfeeding women should not use this medication, and if pregnancy is planned or confirmed, they should consult a physician. It is essential to avoid excessive alcohol consumption while taking this medication, and regular blood tests may be needed as vitamin B12 deficiency can occur. The use of this medication should be temporarily suspended before surgery or tests involving radioactive iodine contrast, and it should be resumed only after kidney function is confirmed to be normal post-surgery. Lastly, this medication should be kept out of the reach of children and stored in the original container to avoid misuse or deterioration.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. The recommended storage temperature is between 1°C and 30°C at room temperature. This helps maintain the medication's effectiveness safely.
Yellow oval biconvex film-coated tablet
30 tablets per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Aprogen Biosciences, Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.